- Home
- REPL vs ZYME Comparison
REPL vs ZYME Comparison
Compare REPL & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REPL
- ZYME
- Stock Information
- Founded
- REPL 2015
- ZYME 2003
- Country
- REPL United States
- ZYME United States
- Employees
- REPL N/A
- ZYME N/A
- Industry
- REPL Biotechnology: Pharmaceutical Preparations
- ZYME Biotechnology: Pharmaceutical Preparations
- Sector
- REPL Health Care
- ZYME Health Care
- Exchange
- REPL Nasdaq
- ZYME Nasdaq
- Market Cap
- REPL 851.0M
- ZYME 983.6M
- IPO Year
- REPL 2018
- ZYME 2017
- Fundamental
- Price
- REPL $9.00
- ZYME $11.86
- Analyst Decision
- REPL Strong Buy
- ZYME Buy
- Analyst Count
- REPL 6
- ZYME 6
- Target Price
- REPL $20.00
- ZYME $19.50
- AVG Volume (30 Days)
- REPL 658.1K
- ZYME 728.6K
- Earning Date
- REPL 05-15-2025
- ZYME 03-05-2025
- Dividend Yield
- REPL N/A
- ZYME N/A
- EPS Growth
- REPL N/A
- ZYME N/A
- EPS
- REPL N/A
- ZYME N/A
- Revenue
- REPL N/A
- ZYME $76,304,000.00
- Revenue This Year
- REPL $31.16
- ZYME $19.85
- Revenue Next Year
- REPL N/A
- ZYME $100.06
- P/E Ratio
- REPL N/A
- ZYME N/A
- Revenue Growth
- REPL N/A
- ZYME 0.38
- 52 Week Low
- REPL $4.92
- ZYME $7.97
- 52 Week High
- REPL $17.00
- ZYME $17.70
- Technical
- Relative Strength Index (RSI)
- REPL 22.80
- ZYME 38.43
- Support Level
- REPL $10.17
- ZYME $11.52
- Resistance Level
- REPL $10.78
- ZYME $13.28
- Average True Range (ATR)
- REPL 0.62
- ZYME 0.57
- MACD
- REPL -0.19
- ZYME -0.01
- Stochastic Oscillator
- REPL 0.00
- ZYME 10.26
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated product candidates. Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.